Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.

Détails

ID Serval
serval:BIB_1A0F365705B6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.
Périodique
Diabetes
Auteur(s)
Burcelin R., Da Costa A., Drucker D., Thorens B.
ISSN
0012-1797[print], 0012-1797[linking]
Statut éditorial
Publié
Date de publication
08/2001
Volume
50
Numéro
8
Pages
1720-1728
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Activation of the hepatoportal glucose sensors by portal glucose infusion leads to increased glucose clearance and induction of hypoglycemia. Here, we investigated whether glucagon-like peptide-1 (GLP-1) could modulate the activity of these sensors. Mice were therefore infused with saline (S-mice) or glucose (P-mice) through the portal vein at a rate of 25 mg/kg. min. In P-mice, glucose clearance increased to 67.5 +/- 3.7 mg/kg. min as compared with 24.1 +/- 1.5 mg/kg. min in S-mice, and glycemia decreased from 5.0 +/- 0.1 to 3.3 +/- 0.1 mmol/l at the end of the 3-h infusion period. Coinfusion of GLP-1 with glucose into the portal vein at a rate of 5 pmol/kg. min (P-GLP-1 mice) did not increase the glucose clearance rate (57.4 +/- 5.0 ml/kg. min) and hypoglycemia (3.8 +/- 0.1 mmol/l) observed in P-mice. In contrast, coinfusion of glucose and the GLP-1 receptor antagonist exendin-(9-39) into the portal vein at a rate of 0.5 pmol/kg. min (P-Ex mice) reduced glucose clearance to 36.1 +/- 2.6 ml/kg. min and transiently increased glycemia to 9.2 +/- 0.3 mmol/l at 60 min of infusion before it returned to the fasting level (5.6 +/- 0.3 mmol/l) at 3 h. When glucose and exendin-(9-39) were infused through the portal and femoral veins, respectively, glucose clearance increased to 70.0 +/- 4.6 ml/kg. min and glycemia decreased to 3.1 +/- 0.1 mmol/l, indicating that exendin-(9-39) has an effect only when infused into the portal vein. Finally, portal vein infusion of glucose in GLP-1 receptor(-/-) mice failed to increase the glucose clearance rate (26.7 +/- 2.9 ml/kg. min). Glycemia increased to 8.5 +/- 0.5 mmol/l at 60 min and remained elevated until the end of the glucose infusion (8.2 +/- 0.4 mmol/l). Together, our data show that the GLP-1 receptor is part of the hepatoportal glucose sensor and that basal fasting levels of GLP-1 sufficiently activate the receptor to confer maximum glucose competence to the sensor. These data demonstrate an important extrapancreatic effect of GLP-1 in the control of glucose homeostasis.
Mots-clé
Animals, Blood Glucose/drug effects, Blood Glucose/metabolism, Catheters, Indwelling, Enzyme-Linked Immunosorbent Assay, Fasting, Femoral Vein, Gastrointestinal Hormones/pharmacology, Glucagon/pharmacology, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Glucose/administration &amp, dosage, Hepatic Veins/physiology, Homeostasis, Infusions, Intravenous, Metabolic Clearance Rate, Mice, Mice, Inbred C57BL, Peptide Fragments/pharmacology, Portal System/physiology, Portal Vein/physiology, Protein Precursors/pharmacology, Tritium, Venoms/pharmacology
Pubmed
Web of science
Création de la notice
24/01/2008 14:41
Dernière modification de la notice
03/03/2018 14:28
Données d'usage